These results demonstrated that constitutive activation of the PI3K pathway is necessary for the survival of AML blasts and that targeting of this pathway with pharmacologic inhibitors may be of clinical benefit in treatment of AML [325]. This evidence concerns the gene PIK3CA and acute myeloid leukemia.